Ascendis Pharma A/S
ASND
185 hedge funds and large institutions have $7.61B invested in Ascendis Pharma A/S in 2023 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 53 increasing their positions, 65 reducing their positions, and 21 closing their positions.
124% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 21
45% more funds holding in top 10
Funds holding in top 10: 11 → 16 (+5)
35% more capital invested
Capital invested by funds: $5.64B → $7.61B (+$1.96B)
30% more call options, than puts
Call options by funds: $26.8M | Put options by funds: $20.7M
16% more funds holding
Funds holding: 160 → 185 (+25)
0.18% more ownership
Funds ownership: 105.48% → 105.66% (+0.18%)
18% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 65
Top Buyers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$35.1M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$25.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$23.5M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$22.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$17.1M |
Top Sellers
ASND Hedge Fund Activity: Q4 2023 in Review
185 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2023, worth a combined $7.61B — up 35% from $5.64B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ASND positions and 21 closed out — a net gain of 26 holders — while 53 added to existing stakes and 65 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $35.1M. The largest seller was RA Capital Management, cutting an estimated $61M.
- 185 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2023, up from 160 in Q3 2023.
- Funds reported $7.61B of Ascendis Pharma A/S stock for Q4 2023, up 35% quarter-over-quarter.
- 47 funds opened new Ascendis Pharma A/S positions in Q4 2023 and 21 closed out, a net change of +26 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2023 was Paradigm Biocapital Advisors, an estimated $35.1M added.
- The largest Ascendis Pharma A/S seller in Q4 2023 was RA Capital Management, an estimated $61M sold.
Based on aggregated 13F filings for Q4 2023.